DOCSLIB.ORG

Aerogenes) Gentamicin, Enterobacter - Subgroup C (Aerobacter Liquefaciens) Flavobacterium

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Aerogenes) Gentamicin, Enterobacter - Subgroup C (Aerobacter Liquefaciens) Flavobacterium DRUGS OF CHOICE FOR nalidixic acid for information concerning the use SPECIFIC BACTERIA of these agents in urinary tract infections. All the drugs effective against a given organism SYDNEY M. FINEGOLD, M.D., AND ALVIN DAVIS, M.D. are not necessarily listed. Drugs listed first are The choices below are not necessarily appropri- usually the most effective or least toxic, or both. ate for urinary tract infection. See sections on sul- Italicized drugs are outstanding in effectiveness fonamides, oral penicillin G, nitrofurantoin and against the particular organism. GRAM-NEGATIVE BACILLI Organism Drag of Choice Achromobacter anitratus ................. Kanamycin, polymyxin or colistin, tetracycline, erythro- mycin Achromobacter lwoffii ................. Tetracycline, kanamycin, polymyxin or colistin, erythro- mycin, chloramphenicol Achromobacter-other species ... Polymyxin or colistin, kanamycin, tetracycline, chloram- phenicol Actinobacillus actinomycetemcomitans ..... Tetracycline, streptomycin, chloramphenicol, ? ampicil- lin, ? penicillin Actinobacillus lignieresii ......... Kanamycin, ? polymyxin or colistin Aeromonas hydrophila .................... Tetracycline, kanamycin, chloramphenicol Arizona ......................... Ampicillin, cephalothin, tetracycline, chloramphenicol Bacteroides fragilis ....................... Tetracycline, chloramphenicol, erythromycin, lincomy- cin, penicillin Bacteroides melaninogenicus .. ............ Penicillin, linomycin, tetracycline, chloramphenicol Bartonella bacilliformis ................... Penicillin C, chloramphenicol, streptomycin, tetracy- cline Bordetella pertussis ........ Ampicillin, tetracycline Brucella........ Tetracycline, chloramphenicol Calymmatobacterium granulomatis .......... Tetracycline, streptomycin, chloramphenicol Chromobacterium ........ Streptomycin, tetracycline, chloramphenicol Citrobacter ........ Polymyxin or colistin, kanamycin, chloramphenicol, tetracycline E. coli ................................ Chloramphenicol, tetracycline, kanamycin, gentamicin, ampicillin, cephalothin, polymyxin SEdwardsiella .......... Tetracycline, chloramphenicol, polymyxin or colistin, ampicillin .Enterobacter -Subgroup A (Aerobacter cloacae) B Enterobacter - Subgroup (Aerobacter kanamycin, polymyxin or colistin aerogenes) Gentamicin, Enterobacter - Subgroup C (Aerobacter liquefaciens) flavobacterium. Chloramphenicol, sulfadiazine Fusobacterium (fusiform bacilli) . ..... Penicillin, lincomycin, tetracycline, chloramphenicol Hafnia ...... Tetracycline, chloramphenicol, kanamycin Hemophilus aphrophilus. Ampicillin, tetracycline, chloramphenicol, streptomycin -Hemophilus ducreyi .................... Tetracycline, sulfonamides, chloramphenicol, strepto- mycin Hemophilus influenzae .................... Tetracycline, chloramphenicol, streptomycin, kanamy- cin, penicillin Klebsiella pneumoniae .................... Gentamicin, kanamycin, polymyxin or colistin Klebsiella rhinoscleromatis ................ Streptomycin, tetracycline, chloramphenicol Moraxella liquefaciens .................... Penicillin, ampicillin, chloramphenicol, tetracycline Moraxella duplex, var. nonliquefaciens ....... Penicillin, tetracycline, kanamycin Pasteurella multocida (septica) ............. Penicillin, tetracycline, chloramphenicol Pasteurella pestis ........................ Streptomycin plus either tetracycline or chloramphenicol Pasteurella pseudotuberculosis ........ Tetracycline, ? chloramphenicol, ? streptomycin Pasteurella (Franciscella) tularensis ..... .... Streptomycin plus either tetracycline or chloramphenicol Proteus mirabilis ....................... Kanamycin, ampicillin, cephalothin or cephaloridine, chloramphenicol, penicillin, gentamicin (Gram-Negative Bacilli, Continued from Page 374) Organism Drag of Cboice Proteus morganin ....................... Kanamycin, chloramrphenicol, gentamicin Proteus rettgeri ........................ Kanamycin, gentamicin Proteus vulgaris ........................ Kanamycin, chloramphenicol, gentamicin Providence ............................ Kanamycin, chloramphenicol, tetracycline, polymyxin or colistin Pseudomonas aeruginosa ................. Gentamicin, polymyxin or colistin, oxytetracycline, chloramphenicol Pseudomonas maltophilia ................. Polymyxin or colistin, chloramphenicol, kanamycin Pseudomonas pseudomallei ............... Chloramphenicol, kanamycin, sulfadiazine, tetracycline Pseudomonas stutzeri .................... Ampicillin, cephalothin, kanamycin, polymyxin or co- listin Salmonela typhi ....................... Chloramphenicol, ampicillin Salmonella, other than S. typhi ............ Chloramphenicol, ampicillin, cephalothin Serratia marcescens ..................... Gentamicin, kanamycin, chloramphenicol Shigela .............................. Ampicillin, cephalothin, kanamycin, tetracycline, chlor- amphenicol Sphaerophorus necrophorus (Bacteroides funduliformis) ............ Tetracycline, chloramphenicol, penicillin, lincomycin Streptobacillus moniliformis ............... Penicillin Vibrio cholerae ......................... Tetracycline, chloramphenicol Vibrio fetus ........................... Tetracycline, chloramphenicol, ampicillin, streptomycin GRAM-NEGATIVE COCCI Gonococcus (Neisseria gonorrhoeae) ....... Penicillin, tetracycline, erythromycin Meningococcus (Neisseria meningitidis). .Penicillin, ampicillin, chloramphenicol, erythromycin, tetracycline, sulfadiazine GRAM-POSITIVE BACILLI Actinomyces israelii ..................... Penicillin, tetracycline, chloramphenicol, cephalothin Bacillus anthracis ....................... Penicillin, erythromycin, tetracycline Clostridium ........................... Penicillin, tetracycline, chloramphenicol Corynebacterium acnes .................. Tetracycline, ? lincomycin Corynebacterium diphtheriae ............. Penicillin, erythromycin, cephalothin Corynebacterium, other .................. Vancomycin, penicillin, erythromycin Erysipelothrix rhusiopathiae .............. Penicillin, ? tetracycline Listeria monocytogenes .................. Tetracycline, ampicillin, penicillin, erythromycin Nocardia ............................. Sulfonamides, cycloserine GRAM-POSITIVE COCCI Pneumococcus (Diplococcus pneumoniae) . Penicillin, erythromycin Staphylococcus. Methicillin, cloxacillin or dicloxacillin, cephalothin or cephaloridine, nafcillin, vancomycin, lincomycin Streptococci Anerobic and microaerophilic strep. (and cocci) ....................... Penicillin, lincomycin, erythromycin, chloramphenicol, vancomycin Enterococci ......................... Penicillin plus streptomycin, chloramphenicol, vanco- mycin, penicillin plus kanamycin, ampicillin, (tetra- cycline for S. liquefaciens) Group A beta-hemolytic strep............ Penicillin, erythromycin, ampicillin, cephalothin Viridans group ....................... Penicillin, vancomycin, cephalothin SPIROCHETES Borrelia recurrentis ..................... Tetracycline, chloramphenicol, penicillin Spirillum minus ........................ Penicillin, erythromycin Treponema palidum .................... Penicillin, erythromycin, tetracycline RICKETTSIAE, MYCOPLASMA, CHLAMYDIA (BEDSONIA) Rickettsia ....... ............ Tetracycline, chloramphenicol Mycoplasma pneumomae .................. Tetracycline, erythromycin Psittacosis (ornithosis) ................... Tetracycline, chloramphenicol Lymphogranuloma venereum ............... Tetracycline, chloramphenicol, sulfonamides.
Load more

Recommended publications
  • Susceptibility of Escherichia Coli to 3-Lactam Antibiotics
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Mar. 1994, p. 494-498 Vol. 38, No. 3 0066-4804/94/$04.00+0 Copyright © 1994, American Society for Microbiology Effect of Hyperproduction of TEM-1 1-Lactamase on In Vitro Susceptibility of Escherichia coli to 3-Lactam Antibiotics PEI-JUN WU,t KEVIN SHANNON,*t AND IAN PHILLIPS Department of Microbiology, United Medical and Dental Schools, St. Thomas' Hospital, London SE1 7EH, United Kingdom Received 21 July 1993/Returned for modification 4 November 1993/Accepted 4 January 1994 The susceptibility of 173 TEM-1-producing isolates of Escherichia coli was assessed by determination of MICs by the agar dilution method. MICs of amoxicillin, mezlocillin, cephaloridine, and, to a smaller extent, amoxicillin-clavulanic acid (but not cephalexin, cefuroxime, cefotaxime, ceftazidime, or imipenem) were higher for isolates that produced large amounts of f8-lactamase than for isolates that produced smaller amounts. The effect of fixed concentrations of clavulanic acid on resistance to amoxicillin was assessed for 34 selected TEM-1-producing isolates. Low concentrations of the inhibitor (0.5 to 1 ,ug/ml) reduced the amoxicillin MICs substantially for almost all the isolates, although the reductions were not sufficient to render any of the isolates amoxicillin susceptible. Higher concentrations of clavulanic acid had progressively greater effects on amoxicillin MICs, but even at 8 ,ug/ml some of the isolates with high P-lactamase activities remained resistant or only moderately susceptible to amoxicillin. All the isolates were inhibited by clavulanic acid (in the absence of amoxicillin) at concentrations of 16 to 32 ,ug/ml. TEM-1 ,-lactamase activity was inhibited in vitro by clavulanic acid, but not totally, with approximately 2% of the initial activity remaining at 2 ,ug/ml and 0.4% remaining at 8 ,guml.
    [Show full text]
  • Are You Suprised ?
    B DAMB 721 Microbiology Final Exam B 100 points December 11, 2006 Your name (Print Clearly): _____________________________________________ I. Matching: The questions below consist of headings followed by a list of phrases. For each phrase select the heading that best describes that phrase. The headings may be used once, more than once or not at all. Mark the answer in Part 2 of your answer sheet. 1. capsid 7. CD4 2. Chlamydia pneumoniae 8. Enterococcus faecalis 3. oncogenic 9. hyaluronidase 4. pyruvate 10. interferon 5. Koplik’s spot 11. hydrophilic viruses 6. congenital Treponema pallidum 12. Streptococcus pyogenes 1. “spreading factor” produced by members of the staphylococci, streptococci and clostridia 2. viral protein coat 3. central intermediate in bacterial fermentation 4. persistant endodontic infections 5. a cause of atypical pneumonia 6. nonspecific defense against viral infection 7. has a rudimentary life cycle 8. HIV receptor 9. Hutchinson’s Triad 10. measles 11. resistant to disinfection 12. β-hemolytic, bacitracin sensitive, cause of suppurative pharyngitis 2 Matching (Continued): The questions below consist of diseases followed by a list of etiologic agents. Match each disease with the etiologic agent. Continue using Part 2 of your answer sheet. 1. dysentery 6. Legionnaire’s 2. botulism 7. gas gangrene 3. cholera 8. tuberculosis 4. diphtheria 9. necrotizing fascitis 5. enteric fever 10. pneumoniae/meningitis 13. Clostridium botulinum 14. Vibrio cholera 15. Mycobacterium bovis 16. Shigella species 17. Streptococcus pneumoniae 18. Clostridium perfringens 19. Salmonella typhi 20. Streptococcus pyogenes 3 II. Multiple Choice: Choose the ONE BEST answer. Mark the correct answer on Part 1 of the answer sheet.
    [Show full text]
  • Pronunciation Guide to Microorganisms
    Pronunciation Guide to Microorganisms This pronunciation guide is provided to aid each student in acquiring a greater ease in discussing, describing, and using specific microorganisms. Please note that genus and species names are italicized. If they cannot be italicized, then they should be underlined (example: a lab notebook). Prokaryotic Species Correct Pronunciation Acetobacter aceti a-se-toh-BAK-ter a-SET-i Acetobacter pasteurianus a-se-toh-BAK-ter PAS-ter-iann-us Acintobacter calcoacetius a-sin-ee-toe-BAK-ter kal-koh-a-SEE-tee-kus Aerococcus viridans (air-o)-KOK-kus vi-ree-DANS Agrobacterium tumefaciens ag-roh-bak-TEAR-ium too-me-FAY-she-ens Alcaligenes denitrificans al-KAHL-li-jen-eez dee-ni-TREE-fee-cans Alcaligenes faecalis al-KAHL-li-jen-eez fee-KAL-is Anabaena an-na-BEE-na Azotobacter vinelandii a-zoe-toe-BAK-ter vin-lan-DEE-i Bacillus anthracis bah-SIL-lus AN-thray-sis Bacillus lactosporus bah-SIL-lus LAK-toe-spore-us Bacillus megaterium bah-SIL-lus Meg-a-TEER-ee-um Bacillus subtilis bah-SIL-lus SA-til-us Borrelia recurrentis bore-RELL-ee-a re-kur-EN-tis Branhamella catarrhalis bran-hem-EL-ah cat-arr-RAH-lis Citrobacter freundii sit-roe-BACK-ter FROND-ee-i Clostridium perfringens klos-TREH-dee-um per-FRINGE-enz Clostridium sporogenes klos-TREH-dee-um spore-AH-gen-ease Clostridium tetani klos-TREH-dee-um TET-ann-ee Corynebacterium diphtheriae koh-RYNE-nee-back-teer-ee-um dif-THEE-ry-ee Corynebacterium hofmanni koh-RYNE-nee-back-teer-ee-um hoff-MAN-eye Corynebacterium xerosis koh-RYNE-nee-back-teer-ee-um zer-OH-sis Enterobacter
    [Show full text]
  • Relapsing Fever in Young Refugees from East Africa Spinello Antinori1,2* , Valeria Colombo1 and Mario Corbellino1,2
    Antinori et al. Critical Care (2017) 21:205 DOI 10.1186/s13054-017-1777-z LETTER Open Access Relapsing fever in young refugees from East Africa Spinello Antinori1,2* , Valeria Colombo1 and Mario Corbellino1,2 See related letter by Cutuli et al. https://ccforum.biomedcentral.com/articles/10.1186/s13054-017-1666-5 We read with interest the letter by Cutuli et al. [1] leptospirosis, all other findings can be observed in describing a case of severe co-infection by Leptospira patients with severe clinical presentation of both dis- spp. and Borrelia recurrentis in a young female refugee eases. However, in the recent wave of LBRF observed in from East Africa. We would like to comment on several Europe, intensivists were faced with severe cases of issues raised by their paper. LBRF presenting with shock solely as a consequence of First, the authors state “nits were present on her the Jarisch-Herxheimer reaction precipitated by adminis- scalp…”. In our opinion, this sentence may mislead tration of antibiotics [4]. readers as meaning that “head lice” (Pediculus humanus A final point that deserves comment concerns the capitis) are the vectors of louse-borne relapsing fever microbiology diagnosis. Molecular biology by means of (LBRF). Indeed, body lice (Pediculus humanus humanus) real-time polymerase chain reaction in this case pro- are to date the only demonstrated vectors of the disease. vided the correct diagnosis of both infections. Although We are aware of only two reports providing proof that not clearly stated, the authors report that malaria was head lice can harbor B. recurrentis and consequently excluded among other possible differential diagnoses.
    [Show full text]
  • Topical Antibiotics for Impetigo: a Review of the Clinical Effectiveness and Guidelines
    CADTH RAPID RESPONSE REPORT: SUMMARY WITH CRITICAL APPRAISAL Topical Antibiotics for Impetigo: A Review of the Clinical Effectiveness and Guidelines Service Line: Rapid Response Service Version: 1.0 Publication Date: February 21, 2017 Report Length: 23 Pages Authors: Rob Edge, Charlene Argáez Cite As: Topical antibiotics for impetigo: a review of the clinical effectiveness and guidelines. Ottawa: CADTH; 2017 Feb. (CADTH rapid response report: summary with critical appraisal). ISSN: 1922-8147 (online) Disclaimer: The information in this document is intended to help Canadian health care decision-makers, health care professionals, health systems leaders, and policy-makers make well-informed decisions and thereby improve the quality of health care services. While patients and others may access this document, the document is made available for informational purposes only and no representations or warranties are made with respect to its fitness for any particular purpose. The information in this document should not be used as a substitute for professional medical advice or as a substitute for the application of clinical judgment in respect of the care of a particular patient or other professional judgment in any decision-making process. The Canadian Agency for Drugs and Technologies in Health (CADTH) does not endorse any information, drugs, therapies, treatments, products, processes, or services. While care has been taken to ensure that the information prepared by CADTH in this document is accurate, complete, and up-to-date as at the applicable date the material was first published by CADTH, CADTH does not make any guarantees to that effect. CADTH does not guarantee and is not responsible for the quality, currency, propriety, accuracy, or reasonableness of any statements, information, or conclusions contained in any third-party materials used in preparing this document.
    [Show full text]
  • Consideration of Antibacterial Medicines As Part Of
    Consideration of antibacterial medicines as part of the revisions to 2019 WHO Model List of Essential Medicines for adults (EML) and Model List of Essential Medicines for children (EMLc) Section 6.2 Antibacterials including Access, Watch and Reserve Lists of antibiotics This summary has been prepared by the Health Technologies and Pharmaceuticals (HTP) programme at the WHO Regional Office for Europe. It is intended to communicate changes to the 2019 WHO Model List of Essential Medicines for adults (EML) and Model List of Essential Medicines for children (EMLc) to national counterparts involved in the evidence-based selection of medicines for inclusion in national essential medicines lists (NEMLs), lists of medicines for inclusion in reimbursement programs, and medicine formularies for use in primary, secondary and tertiary care. This document does not replace the full report of the WHO Expert Committee on Selection and Use of Essential Medicines (see The selection and use of essential medicines: report of the WHO Expert Committee on Selection and Use of Essential Medicines, 2019 (including the 21st WHO Model List of Essential Medicines and the 7th WHO Model List of Essential Medicines for Children). Geneva: World Health Organization; 2019 (WHO Technical Report Series, No. 1021). Licence: CC BY-NC-SA 3.0 IGO: https://apps.who.int/iris/bitstream/handle/10665/330668/9789241210300-eng.pdf?ua=1) and Corrigenda (March 2020) – TRS1021 (https://www.who.int/medicines/publications/essentialmedicines/TRS1021_corrigenda_March2020. pdf?ua=1). Executive summary of the report: https://apps.who.int/iris/bitstream/handle/10665/325773/WHO- MVP-EMP-IAU-2019.05-eng.pdf?ua=1.
    [Show full text]
  • Lice, Rodents, and Many Hopes: a Rare Disease in a Young Refugee Salvatore L
    Cutuli et al. Critical Care (2017) 21:81 DOI 10.1186/s13054-017-1666-5 LETTER Open Access Lice, rodents, and many hopes: a rare disease in a young refugee Salvatore L. Cutuli1, Gennaro De Pascale1*, Teresa Spanu2, Antonio M. Dell’Anna1, Maria G. Bocci1, Federico Pallavicini3, Fabiola Mancini4, Alessandra Ciervo4 and Massimo Antonelli1 Keywords: Migrants, Borrelia recurrentis, Leptospira, Borreliosis, Leptospirosis Migrants from countries with scarce resources represent Leptospira species, Borrelia species, Leishmania species, an increasing worldwide phenomenon providing a daily and Malaria species related infections. challenge for governments and humanitarian organiza- On day 3, the blood and urine samples were positive on tions [1, 2]. real-time polymerase chain reaction (PCR) [3, 4] for Lep- A teenage refugee from East Africa was admitted to tospira spp. (Fig. 1a) and Borrelia recurrentis (only in the our intensive care unit (ICU) with acute respiratory dis- blood sample; Fig. 1b). Antibiotic therapy with 100 mg tress syndrome (ARDS), hypotension, and jaundice. Nits doxycycline every 12 h and 2 g ceftriaxone every 12 h was were present on her scalp and she had no relevant past started, leading to a progressive improvement of the medical history. She arrived in Italy after travelling for patient’s clinical status. On day 21 she was moved to the 7 months under poor hygienic conditions. infectious disease ward, and 10 days later she ran away the ARDS was managed with protective mechanical venti- hospital and has never come back for clinic follow-up. lation (tidal volume 350 ml, plateau pressure 28 Borrelia recurrentis infection is a louse-borne disease cmH2O), high positive end-expiratory pressure (15 and Leptospirosis is a rat-borne zoonosis, both endemic in cmH2O), neuromuscular blocking agents, prone posi- areas characterized by a low hygiene condition.
    [Show full text]
  • WO 2010/025328 Al
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date 4 March 2010 (04.03.2010) WO 2010/025328 Al (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every A61K 31/00 (2006.01) kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, (21) International Application Number: CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, PCT/US2009/055306 DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, (22) International Filing Date: HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, 28 August 2009 (28.08.2009) KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, (25) Filing Language: English NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, (26) Publication Language: English SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (30) Priority Data: 61/092,497 28 August 2008 (28.08.2008) US (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, (71) Applicant (for all designated States except US): FOR¬ GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, EST LABORATORIES HOLDINGS LIMITED [IE/ ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, —]; 18 Parliament Street, Milner House, Hamilton, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, Bermuda HM12 (BM).
    [Show full text]
  • Distinct Penicillin Binding Proteins Involved in the Division
    Proc. Nat. Acad. Sci. USA Vol. 72, No. 8, pp. 2999- , August 1975 Biochemistry Distinct penicillin binding proteins involved in the division, elongation, and shape of Escherichia coli K12 (P-lactam antibiotics/slab gel electrophoresis/binding protein mutants) BRIAN G. SPRATT Department of Biochemical Sciences, Moffett Laboratories, Princeton University, Princeton, New Jersey 08540 Communicated by Arthur B. Pardee, May 20,1975 ABSTRACT The varied effects of #-lactam antibiotics on ied effects of f3-lactam antibiotics by their relative affinities cell division, cell elongation, and cell shape in E. coil are for three proteins involved in cell division, elongation, and shown to be due to the presence of three essential penicillin binding proteins with distinct roles in these three processes. the maintenance of cell shape. (A) Cell shape: ,-Lactams that specifically result in the pro- duction of ovoid cells bind to penicillin binding protein 2 METHODS (molecular weight 66,000). A mutant has been isolated that The organism used in these studies was E. coil K12 (strain fails to bind ft-lactams to protein 2, and that grows as round cells. (B) Cell division: f-Lactams that specifically inhibit cell KN126). It was grown in Difco Pennassay broth at 370 with division bind preferentially to penicillin binding protein 3 vigorous aeration and harvested at late logarithmic phase. (molecular weight 60,000). A temperature-sensitive cell divi- Mutants B6 and 6-30 were grown in the same medium at sion mutant has been shown to have a thermolabile protein 300. 3. (C) Cell elongation: One ft-lactam that preferentially inhib- Assay of Penicillin Binding Proteins.
    [Show full text]
  • Appraisal of Multifarious Brands of Cephradine for Their in Vitro Antibacterial Activity Against Varied Microorganisms
    Appraisal of multifarious brands of Cephradine for their in vitro antibacterial activity against varied microorganisms Sajid Bashir1, Shamshad Akhtar1, Shahzad Hussain*2, Farnaz Malik2, Sidra Mahmood3, Alia Erum1 and Ume-Ruqiatulain1 1Department of Pharmacy, Sargodha University, Sargodha, Pakistan 2National Institute of Health, Islamabad, Pakistan 3Department of Bioinformatics and Biotechnology, International Islamic University, Islamabad, Pakistan Abstract: The astounding and exceptional growth of generic pharmaceutical Industry in Pakistan has raised certain questions for drug regulatory authorities contemplating their efficacy and quality. The current study focuses on assessing the in-vitro antimicrobial activity of 24 brands of Cephradine 500mg capsules against 4 different strains by employing standardized methods. Disk diffusion method was performed on all brands to look into the susceptibility and resistance patterns. Standard disk of 5µg Cephradine powder were used during evaluation. The zones of inhibitions were ranged from 24-40mm against S. aureus, 24-40mm against E. coli, 20-25mm against K. pneumonia and 19-23mm P. mirabilis. On the basis of mean value, the multinational brands were found to have better zone of inhibitions and were better than local Pharmaceutical companies but ANOVA cooperative study showed that all brands of Cephradine showed similar comparable results. Further investigations by employing MIC method, quality of raw material with special emphasis on the shelf-life, excepients and method of manufacturing will be needed to obtain more authenticated results. The price of National and Multinational brands ranges from Rs.156.00-212.00 for 10 capsules. It is concluded that Public health is at risk because of noticeable growing widespread curse of the manufacture and trade of sub-standard or below par pharmaceuticals.
    [Show full text]
  • Borrelia Species
    APPENDIX 2 Borrelia Species Likelihood of Secondary Transmission: • Secondary transmission of relapsing fever from blood Disease Agent: exposure or blood contact with broken skin or con- • Borrelia recurrentis—Tick-borne relapsing fever junctiva, contaminated needles • B. duttoni—Louse-borne relapsing fever At-Risk Populations: Disease Agent Characteristics: • Persons with exposure to the tick vector and people living in crowded conditions with degraded public • Not classified as either Gram-positive or Gram- health infrastructure negative, facultatively intracellular bacterium • Order: Spirochaetales; Family: Spirochaetaceae Vector and Reservoir Involved: • Size: 20-30 ¥ 0.2-0.3 mm • Nucleic acid: Approximately 1250-1570 kb of DNA • Argasid (soft) ticks: Tick-borne (endemic) relapsing fever. Rodents are the reservoir. Disease Name: • Human body louse: Louse-borne (epidemic) relaps- ing fever. No nonhuman reservoir • Relapsing fever Blood Phase: Priority Level: • Bacteria are present in high numbers in the blood • Scientific/Epidemiologic evidence regarding blood during febrile episodes and at lower levels between safety: Very low fevers. • Public perception and/or regulatory concern regard- • The duration of bacteremia is not well characterized, ing blood safety: Absent but recurrent fevers can persist for several weeks to • Public concern regarding disease agent: Very low months. Background: Survival/Persistence in Blood Products: • Relapsing fevers occur throughout the world, with the • No information for B. recurrentis; however, laboratory exception of a few areas in the Southwest Pacific. The studies indicate that B. burgdorferi survives in fresh distribution and occurrence of endemic tick-borne frozen plasma, RBCs, and platelets for the duration of relapsing fever (TBRF) are governed by the presence their storage period.
    [Show full text]
  • The Approved List of Biological Agents Advisory Committee on Dangerous Pathogens Health and Safety Executive
    The Approved List of biological agents Advisory Committee on Dangerous Pathogens Health and Safety Executive © Crown copyright 2021 First published 2000 Second edition 2004 Third edition 2013 Fourth edition 2021 You may reuse this information (excluding logos) free of charge in any format or medium, under the terms of the Open Government Licence. To view the licence visit www.nationalarchives.gov.uk/doc/ open-government-licence/, write to the Information Policy Team, The National Archives, Kew, London TW9 4DU, or email [email protected]. Some images and illustrations may not be owned by the Crown so cannot be reproduced without permission of the copyright owner. Enquiries should be sent to [email protected]. The Control of Substances Hazardous to Health Regulations 2002 refer to an ‘approved classification of a biological agent’, which means the classification of that agent approved by the Health and Safety Executive (HSE). This list is approved by HSE for that purpose. This edition of the Approved List has effect from 12 July 2021. On that date the previous edition of the list approved by the Health and Safety Executive on the 1 July 2013 will cease to have effect. This list will be reviewed periodically, the next review is due in February 2022. The Advisory Committee on Dangerous Pathogens (ACDP) prepares the Approved List included in this publication. ACDP advises HSE, and Ministers for the Department of Health and Social Care and the Department for the Environment, Food & Rural Affairs and their counterparts under devolution in Scotland, Wales & Northern Ireland, as required, on all aspects of hazards and risks to workers and others from exposure to pathogens.
    [Show full text]